New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 11, 2014
11:42 EDTCOVCovidien liability from recall appears limited, says Brean Capital
Brean Capital believes Covidien's liability from its voluntary recall of certain embolization and retrieval devices appears limited, noting that there were no deaths associated with the issue and only products distributed from May 2013 are affected. The firm estimates the impact for the recall is about $5M-$10M, which translates to about a 1c-2c impact to EPS, which should be offset by other parts of the business. Brean maintains its Buy rating and $75 price target on Covidien.
News For COV From The Last 14 Days
Check below for free stories on COV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
07:05 EDTCOVCovidien acquires Sapheon, terms not disclosed
Covidien announced that it has acquired Sapheon, Inc., a privately-held developer of venous disease treatments. Financial terms of the transaction were not disclosed.
August 26, 2014
19:33 EDTCOVCovidien shareholder sues to block sale to Medtronic, Bloomberg reports
Subscribe for More Information
August 22, 2014
07:01 EDTCOVCovidien acquires Reverse Medical, terms not disclosed
Subscribe for More Information
August 20, 2014
07:18 EDTCOVMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
08:22 EDTCOVMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
August 18, 2014
16:10 EDTCOVCovidien says study shows directional atherectomy safe, effective
Covidien announced that directional atherectomy is "safe and effective as a frontline therapy for the treatment of peripheral arterial disease," according to a Covidien study published online today in the Journal of American College of Cardiology, Cardiovascular Interventions. Results from the DEFINITIVE LE study using Covidienís TurboHawk and/or SilverHawk directional atherectomy systems demonstrated 95% limb salvage in patients with critical limb ischemia and 78% overall patency in claudicant patients at 12 months.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use